The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Beiersdorf Implements Sopheon System in Support of Product Innovation Strategy

16 Oct 2007 14:38

Sopheon, the international software and services company,announced today that Beiersdorf AG, a leading manufacturer of skin andbeauty care products, has deployed Sopheon's Accolade product lifecycle management (PLM) system to support the company's implementationof an enhanced, integrated process for developing and launching newproducts. The solution is also being used to strengthen productportfolio decision-making and reporting. £ Founded in Hamburg, Germany in 1882 by pharmacist Carl Beiersdorf,Beiersdorf's original product patents were for bandages and woundcoverings. By the turn of the century, the company had expanded intoconsumer skin care and beauty products. Today Beiersdorf is a $7Bglobal producer of regionally branded consumer goods withapproximately 100 locations and more than 17,000 employees. Thecompany has a reputation for strong customer and product focus, anorientation that has helped, for instance, make NIVEA(R) thebest-selling body care brand in the world. £ Cosmetics is a highly competitive, global industry. It is alsoamong the fastest-moving markets in the consumer goods sector. Thelife of a typical cosmetic product is only about four years, whichmeans that ongoing, rapid innovation is a prerequisite to achievingsustained business growth. Beiersdorf is addressing this imperative asa core aspect of its consumer business strategy, labeled "Passion forSuccess." The strategy calls for the company to focus on fewer butmore significant innovations and deliver them to market faster.Beiersdorf has long regarded continuous improvement of its new productdevelopment processes as a key factor in maintaining brandsuperiority. £ Beiersdorf's adoption of Accolade has allowed the company toadvance not only its processes for product creation, but its portfoliomanagement capabilities as well. One principal benefit of the systemis that it has given the cross-functional teams engaged in productdevelopment across the Beiersdorf organization a common platformthrough which to access and share project data. The result has beengreater transparency and an improved ability to track the progress ofprojects in the developmental pipeline. Accolade has also helped toraise the efficiency and accuracy of portfolio reporting andstrengthen the company's portfolio management and decision-makingprocesses. £ Sopheon partners, Sopheon Vertriebs GmbH and Sopheon BusinessApplications GmbH, were responsible for the sale, implementation andsupport of Accolade at Beiersdorf. Dieter Jaeger, chief executiveofficer of Sopheon Vertriebs GmbH, said, "Beiersdorf has commanded atop position in the international personal care market for many years,and innovation-led product development has been a hallmark of theirsuccess. When we were introduced to Beiersdorf, they already had inplace a standardized, global product development process anchored inbest practices. With Accolade, we were able to give them a single,user-friendly software system that integrated the management of thatprocess with portfolio management and comprehensive decision-support.Beiersdorf chose Accolade because it could match their specific,demanding process requirements. They have subsequently embraced itbecause it has proven that it helps to ensure superior processperformance." £ Accolade(R) is a registered trademark of Sopheon plc. £ NIVEA(R) is a registered trademark of Beiersdorf AG. £ All other trademarks and registered trademarks are the soleproperty of their respective owners. £ About Beiersdorf AG £ Founded in Hamburg, Germany in 1882 as a small pharmacy,Beiersdorf has grown to become a global company of branded consumergoods with approximately 100 affiliates. Since its founding,Beiersdorf has concentrated on skin and beauty care. Beiersdorf isfocused on dynamic regions that have above-average developmentalpotential, including Asia, South America and Eastern Europe.Beiersdorf is particularly focused on China, Russia, Brazil and India.Beiersdorf products include NIVEA(R), Eucerin(R), Curad(R),Labello(R), 8x4(R), JUVENA(R), la prairie(R), atrix(R) and FUTURO(R).For more information, please visit www.beiersdorf.com. £ About Sopheon £ Sopheon (LSE:SPE) is an international provider of software andservices that help organizations improve the business impact ofproduct innovation. Sopheon's solutions automate and govern theinnovation process, enabling companies to increase revenue and profitsfrom new products. Sopheon is listed on the AIM Market of the LondonStock Exchange and on the Euronext in the Netherlands. For moreinformation, please visit www.sopheon.com. Copyright Business Wire 2007
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.